- White Sox heading for worst season in MLB history
- Hong Kong democracy tycoon's son warns time running out
- New migraine drugs no better than cheap painkillers: big study
- Sean 'Diddy' Combs again denied bail in sex trafficking case
- Brewers clinch division title as MLB playoff race heats up
- US stocks dip despite larger Fed interest rate cut
- Man City held by Inter as PSG pinch win in Champions League
- All Blacks recall Beauden Barrett for Australia Test
- Spurs late show saves Postecoglou blushes at Coventry
- PSG snatch late goal to beat Champions League debutants Girona
- Gittens' late double gives Dortmund Champions League win at Brugge
- Man City blunted by Inter in Champions League stalemate
- Hidden talent: French Olympic star Marchand opts for disguise
- MrBeast named in California lawsuit over 'Beast Games' show
- Gauff splits with Gilbert as coach after 14-month run
- Hundreds of thousands at risk in Sudan's El-Fasher: UN
- Harvey Weinstein pleads not guilty to new sex crime charge
- Venezuelan opposition candidate says letter conceding election was coerced
- X update allows app to bypass Brazil ban: internet providers
- Arsenal's Odegaard faces lengthy injury absence
- India coal expansion risks massive methane growth: report
- China the top challenge in US history, top diplomat says
- Ronaldo's Al Nassr appoint former AC Milan boss Pioli
- Ainslie 'relieved' as British book place in Louis Vuitton Cup final
- Women's NBA will add 15th team in Portland in 2026
- Brazil fires need harsher punishment: environmental police boss
- Boeing to start large temporary furloughs amid Seattle strike
- Fears of all-out war as new Lebanon device blasts kill nine, wound 300
- 'Emergency' declared over falling UK butterfly numbers
- Stock markets, dollar slip before US rate decision
- Russian advance in Kursk 'stopped': Ukraine official to AFP
- UN members demand end to 'unlawful' Israeli occupation of Palestinian territories
- Snapchat pushes 'safer' platform image, but not everyone agrees
- So where does the oceans' plastic waste come from?
- Allied war heroes buried in Netherlands... 80 years on
- Marsh coy over Australia's choice to open alongside Head
- New London sculpture pays tribute to trans community
- Lebanon doctors tell of horror after pager blasts
- McIlroy eyes Wentworth glory after Irish Open collapse
- Italy seen overtaking France as world's largest wine producer
- Hezbollah vows vengeance on Israel for pager blasts
- Brook expects unified England after McCullum's white-ball takeover
- Kamindu Mendis century rescues Sri Lanka against New Zealand
- Two dead in botched armed raid on Russian retailer's office
- UK train drivers back govt pay deal to end strikes
- Man who copied French rapist says he deserves to punished
- Eriksen will wait to settle Man Utd future
- Former England striker Carroll signs for fourth-tier Bordeaux
- Van Dijk hails Liverpool's 'calm' response in win over AC Milan
- End of the party? Tupperware files for bankruptcy
RBGPF | 5.79% | 60.5 | $ | |
BCC | 1.33% | 137.06 | $ | |
AZN | 0.06% | 78.58 | $ | |
GSK | -0.31% | 42.43 | $ | |
SCS | 0.71% | 14.11 | $ | |
NGG | -0.46% | 70.05 | $ | |
BTI | -0.34% | 37.88 | $ | |
CMSC | 0.02% | 25.055 | $ | |
RELX | -0.82% | 47.37 | $ | |
CMSD | -0.12% | 24.98 | $ | |
RIO | -0.02% | 62.91 | $ | |
JRI | 0.45% | 13.44 | $ | |
BCE | 3.09% | 35.61 | $ | |
VOD | 0.49% | 10.23 | $ | |
RYCEF | 1.37% | 6.55 | $ | |
BP | -0.37% | 32.43 | $ |
High doses of Adderall linked with heightened risk of psychosis and mania
Adderall is an effective treatment for attention deficit hyperactivity disorder (ADHD), but a sharp rise in US prescriptions over the past two decades has sparked concerns among researchers about rare but serious side effects.
In a striking new study published Thursday, a team led by psychiatrist Lauren Moran of Mass General Brigham in Boston found that individuals taking high doses of the stimulant face more than a fivefold increased risk of developing psychosis or mania.
Key factors include the lack of upper dosing guidelines and the notable increase in young adults using the medicine since the Covid-19 pandemic, driven in large part by the rise of telemedicine providers.
Moran told AFP her interest grew from her time at a hospital inpatient unit treating college students in the greater Boston area.
"We were just seeing a lot of people coming in without much of a psychiatric history, developing the first episode of psychosis or mania in the context of using prescription stimulants," she said.
When the Food and Drug Administration became aware of such cases in the 2000s, it added a warning to the drug's label -- but relatively little research had been done to quantify the rates of side effects or how they related to the dosage level.
For their investigation, Moran and colleagues reviewed the electronic health records of people aged 16 to 35 admitted at Mass General Brigham hospitals between 2005 and 2019. That is the typical onset ages for psychosis, or losing touch with reality.
The researchers identified 1,374 individuals experiencing their first episode of psychosis or mania -- a disruptive state characterized by high energy, erratic behavior -- and compared them to 2,748 control patients who were hospitalized for other psychiatric conditions.
By analyzing Adderall use during the previous month and adjusting for other variables like substance use, they were able to specifically determine the impact of stimulants.
They found those who had taken Adderall were 2.68 times more likely to have been hospitalized with psychosis or mania compared to those who were not -- and this increased to 5.28 times more likely at higher doses of 40 milligrams and above.
A separate analysis found no increased risk with Ritalin, another stimulant prescribed for ADHD. Moran suggested this could be due to key differences in how the two drugs work.
- Telemedicine companies -
Both medications raise dopamine levels, a chemical messenger involved in the brain's reward system, motivation, and learning. However, while Adderall, an amphetamine, increases dopamine release, Ritalin works by blocking its reabsorption.
For Moran, a critical takeaway was the need for clear upper dose limits on labels. The current label recommends treating patients with 20 milligrams, but in practice, doctors vary widely in their prescriptions.
This variability partly stems from severe impairment in ADHD symptoms that require higher doses, but Moran has occasionally observed "carelessness in dose prescribing," while at other times, patients may "shop" for a doctor willing to prescribe what they want.
"People, including clinicians, might think they can eliminate all ADHD symptoms, but that's not a realistic expectation," she added.
Telemedicine companies, in particular, have come under scrutiny for allegedly overprescribing Adderall, contributing to shortages for those who genuinely need the medication.
The Drug Enforcement Administration, which had proposed revoking telehealth prescriptions for Adderall, extended them through the end of 2024 in response to significant public feedback.
G.Machado--PC